Final results from an open-label, single-center, hybridvirtual 12-month trial of Lunasin for patients with ALS

Category Primary study
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Year 2017
This article has no abstract
Epistemonikos ID: b1a37275081fb549f108aae472a7c6307ee72912
First added on: Feb 08, 2025